C14orf145 Inhibitors
C14orf145 is a protein whose activity is intricately linked to the mTOR signaling pathway, a central regulator of cell growth and metabolism. Inhibition of mTOR not only disrupts the downstream signaling cascade but also directly impacts the functional activity of C14orf145. Specific inhibitors target the mTOR complex, directly impeding its kinase activity, which in turn diminishes the downstream effects necessary for C14orf145-mediated cellular processes. These inhibitors work by forming complexes with intracellular proteins like FKBP12, selectively binding to mTOR complex 1, or acting broadly on both mTORC1 and mTORC2. By blocking the phosphorylation events that are crucial for the mTOR pathway, the inhibitors effectively reduce the functional output of C14orf145, thus preventing it from executing its role in cell proliferation and growth.
Furthermore, the inhibition of upstream kinases such as AKT by other compounds leads to a reduction in mTOR activity, which results in decreased C14orf145 signaling. The suppression of AKT phosphorylation indirectly affects C14orf145 by limiting the mTORC1/C2-mediated signaling pathways it relies on for activation and function. The comprehensive inhibition of these signaling pathways, either by dual TORC1/TORC2 inhibitors or ATP-competitive inhibitors that disrupt mTOR's kinase activity, ensures a thorough downregulation of C14orf145 activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 that binds to mTOR, inhibiting its kinase activity which directly impacts C14orf145 by reducing its associated downstream signaling required for cell growth and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase inhibitor that prevents phosphorylation of AKT, leading to reduced mTOR activity, which would decrease the activity of C14orf145 due to lessened mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is another phosphoinositide 3-kinase inhibitor, similar to Wortmannin, which suppresses AKT phosphorylation and subsequent mTOR pathway signaling, diminishing C14orf145 function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the phosphorylation and activation of AKT, which is upstream of mTOR, thereby reducing C14orf145 activity by limiting mTORC1/C2-mediated signaling. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus selectively binds to mTOR complex 1 (mTORC1) and inhibits its activity, which in turn diminishes the function of C14orf145 by lessening the downstream signaling cascade. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is an mTOR inhibitor that acts broadly on mTORC1 and mTORC2 complexes, suppressing the signaling pathways that are crucial for C14orf145 activity. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $315.00 $1799.00 | ||
A selective ATP-competitive inhibitor of mTOR that diminishes C14orf145 function by inhibiting the mTOR signaling pathway it relies on. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is a selective inhibitor of mTOR kinase, which leads to decreased mTOR signaling, thereby reducing the functional activity of C14orf145. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 is a dual TORC1/TORC2 inhibitor, impairing both the mTORC1 and mTORC2 complexes that are necessary for the full activation of C14orf145. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU 0063794 directly inhibits both mTORC1 and mTORC2 complexes, which are involved in the signaling pathways that regulate C14orf145 activity. | ||||||